tag:blogger.com,1999:blog-68450584067685289192024-03-18T01:15:40.917-07:00Biotech SFSan Francisco Bay Area biotech stories.Anonymoushttp://www.blogger.com/profile/02615979727918182784noreply@blogger.comBlogger1317125tag:blogger.com,1999:blog-6845058406768528919.post-60442466798890520232012-11-13T05:09:00.001-08:002012-11-13T05:10:16.270-08:00Stanford team wins $20K for algorithm aimed at Lou Gehrig's disease drug trials<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;"><tbody>
<tr><td style="text-align: center;"><a href="http://2.bp.blogspot.com/-Ws16-aTKsJY/UKJGiIL-98I/AAAAAAAABbg/N11ZDPbiAkQ/s1600/MackeyLester.jpeg" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" height="200" src="http://2.bp.blogspot.com/-Ws16-aTKsJY/UKJGiIL-98I/AAAAAAAABbg/N11ZDPbiAkQ/s200/MackeyLester.jpeg" width="165" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Lester Mackey.</td></tr>
</tbody></table>
<span style="background-color: white; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;"><a href="http://www.bizjournals.com/sanfrancisco/blog/biotech/2012/11/stanford-als-lou-gehrigs-prize4life.html">A team from Stanford University won $20,000 for its work with algorithms that could reduce the number of Lou Gehrig’s Disease patients needed in clinical trials.</a></span><a href="http://www.bizjournals.com/sanfrancisco/search/results?q=Lester%20Mackey" style="background-color: white; color: #1d5db1; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px; padding-right: 0px; text-decoration: initial;">Lester Mackey</a><span style="background-color: white; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;">, a postdoctoral candidate in mathematics and statistics at Stanford, and </span><a href="http://www.bizjournals.com/sanfrancisco/search/results?q=Lilly%20Fang" style="background-color: white; color: #1d5db1; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px; padding-right: 0px; text-decoration: initial;">Lilly Fang</a><span style="background-color: white; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;">, a recent juris doctor and master’s degree recipient, won the award from Prize4Life, a Cambridge, Mass.-based nonprofit organization set up to accelerate the discovery of treatments and a cure for Lou Gehrig’s disease, or amyotrophic lateral sclerosis.</span>Anonymoushttp://www.blogger.com/profile/02615979727918182784noreply@blogger.com0tag:blogger.com,1999:blog-6845058406768528919.post-47939177275023465392012-11-13T05:04:00.000-08:002012-11-13T05:04:55.385-08:00Pearl Therapeutics grabs $65M in VC funding, moves COPD drug toward Phase III trials<div class="separator" style="clear: both; text-align: center;">
<a href="http://1.bp.blogspot.com/-BFFvzHA9dJc/UKJFaSu-PqI/AAAAAAAABbY/Zrnhw5Sgc4I/s1600/Pearl+logo.jpeg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" height="51" src="http://1.bp.blogspot.com/-BFFvzHA9dJc/UKJFaSu-PqI/AAAAAAAABbY/Zrnhw5Sgc4I/s200/Pearl+logo.jpeg" width="200" /></a></div>
<a href="http://www.bizjournals.com/sanfrancisco/blog/biotech/2012/11/copd-pearl-therapeutics-theravance-gsk.html" style="background-color: white; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;">Its main competition is seeking approval of a treatment for the lung disease COPD, but the leaders of Pearl Therapeutics Inc., and investors who just ponied up $65 million to push the company’s own COPD drug into Phase III trials, are unbowed.</a><br />
<div style="background-color: white; border: 0px; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px; outline: 0px; padding: 0px 20px 20px 0px; vertical-align: baseline;">
Redwood City-based Pearl said Tuesday that current investors <a class="ct saveLink" ct="APT: Company Link" href="http://www.bizjournals.com/profiles/company/us/ca/menlo_park/5am_ventures/185031" style="color: #1d5db1; padding-right: 0px; text-decoration: initial;">5AM Ventures</a>, Clarus Ventures and <a class="ct saveLink" ct="APT: Company Link" href="http://www.bizjournals.com/profiles/company/us/ca/menlo_park/new_leaf_venture_partners/143200" style="color: #1d5db1; padding-right: 0px; text-decoration: initial;">New Leaf Venture Partners</a> participated in the Series D round led by Vatera Healthcare Partners.<br />
Pearl will use the cash to start a Phase III program for its lead drug candidate, PT-003, for patients with chronic obstructive pulmonary disorder. That treatment is a combination of glycopyrrolate, which is a long-acting muscarinic antagonist, or LAMA, and formoterol fumarate, a long-acting beta-2 agonist, or LABA.</div>
Anonymoushttp://www.blogger.com/profile/02615979727918182784noreply@blogger.com0tag:blogger.com,1999:blog-6845058406768528919.post-56945359848560228362012-11-12T15:50:00.002-08:002012-11-12T15:51:06.514-08:00Nation's HIV research general Tony Fauci: Cure in 'discovery phase'<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;"><tbody>
<tr><td style="text-align: center;"><a href="http://3.bp.blogspot.com/-wc76Jd0-UEI/UKGLEIxIL-I/AAAAAAAABa4/o48v71hkbO0/s1600/FauciTony.JPG" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" height="200" src="http://3.bp.blogspot.com/-wc76Jd0-UEI/UKGLEIxIL-I/AAAAAAAABa4/o48v71hkbO0/s200/FauciTony.JPG" width="150" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Dr. Tony Fauci.</td></tr>
</tbody></table>
<a href="http://www.bizjournals.com/sanfrancisco/blog/biotech/2012/11/tony-fauci-aids-hiv-truvada-gilead.html" style="background-color: white; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;">As director of the National Institute of Allergy and Infectious Diseases for the past 28 years, Tony Fauci has seen the fight against the AIDS virus travel from only a hope for treatment to serious talk of a cure.</a><br />
<div style="background-attachment: initial; background-clip: initial; background-color: white; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 20px; padding-left: 0px; padding-right: 20px; padding-top: 0px; vertical-align: baseline;">
But, Fauci warned, an AIDS cure still is only in the discovery phase.<br />
Speaking last week, as he keynoted the Centers for AIDS Research's national scientific symposium at the <a class="ct saveLink" ct="APT: Company Link" href="http://www.bizjournals.com/profiles/company/us/ca/san_francisco/university_of_california_san_francisco/3240762" style="color: #1d5db1; padding-right: 0px; text-decoration: none;">University of California, San Francisco's</a> Mission Bay campus, Fauci said there are several avenues for fighting HIV but patients must follow treatments for those treatments to be effective. That includes Truvada, from Foster City-based Gilead Sciences Inc (NASDAQ: GILD)., that was recently approved for pre-exposure prophylaxis, or PrEP.<br />
After his address, Fauci spoke with me about HIV treatments, HIV and aging and the road to a cure.</div>
Anonymoushttp://www.blogger.com/profile/02615979727918182784noreply@blogger.com1tag:blogger.com,1999:blog-6845058406768528919.post-47647004891284044222012-11-12T15:41:00.001-08:002012-11-12T15:41:30.624-08:00Stanford self-healing skin could someday shield smartphones<a href="http://www.bizjournals.com/sanjose/blog/2012/11/stanford-self-healing-skin-could-soon.html" style="background-color: white; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;">If all goes according to plan for researchers at Stanford University, a new synthetic skin technology could have big implications for both the medical world and your smartphone.</a><br />
<div style="background-attachment: initial; background-clip: initial; background-color: white; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 20px; padding-left: 0px; padding-right: 20px; padding-top: 0px; vertical-align: baseline;">
The plastic skin developed at Stanford is the first synthetic material that is both touch-sensitive and able to heal itself when torn or cut, according to an article out this week in the journal <em style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; font-family: arial; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: baseline;">Nature Nanotechnology</em>.</div>
Anonymoushttp://www.blogger.com/profile/02615979727918182784noreply@blogger.com0tag:blogger.com,1999:blog-6845058406768528919.post-54624827625383294172012-11-12T09:09:00.003-08:002012-11-12T09:10:53.203-08:00New wave of local companies tackles Lou Gehrig's disease<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;"><tbody>
<tr><td style="text-align: center;"><a href="http://4.bp.blogspot.com/-sb69wr5g3fs/UKEtHERTOuI/AAAAAAAABaY/2-MAPSP_5NA/s1600/local-companies-tackle-lou-gehrigs.jpeg" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" height="132" src="http://4.bp.blogspot.com/-sb69wr5g3fs/UKEtHERTOuI/AAAAAAAABaY/2-MAPSP_5NA/s200/local-companies-tackle-lou-gehrigs.jpeg" width="200" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Patrizia Fanara and David Fineman of KineMed.</td></tr>
</tbody></table>
<a href="http://www.bizjournals.com/sanfrancisco/print-edition/2012/11/09/local-companies-tackle-lou-gehrigs.html?page=all" style="background-color: white; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;">Hoping to find clues for unlocking potentially lucrative cures to diseases such as Alzheimer’s, drug development companies are starting with a more obscure but equally devastating condition: Lou Gehrig’s disease.</a><br />
<div style="background-attachment: initial; background-clip: initial; background-color: white; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 20px; padding-left: 0px; padding-right: 20px; padding-top: 0px; vertical-align: baseline;">
Five Bay Area companies and at least four local research institutions are working on programs in Lou Gehrig’s, or amyotrophic lateral sclerosis., which over three to five years gradually immobilizes patients’ bodies while their minds remain sharp.<br />
What’s more, they’re finding success.<br />
Each of the companies is pursuing different ALS bets, indicating how little is really known about the disease. But their goals are the same: In the short term, expand the options for the 30,000 ALS patients in the United states beyond the single drug that exists today. Longer term, they hope to use what they learn to target more prevalent diseases such as Alzheimer’s.</div>
Anonymoushttp://www.blogger.com/profile/02615979727918182784noreply@blogger.com0tag:blogger.com,1999:blog-6845058406768528919.post-92033089649610587732012-11-12T09:01:00.002-08:002012-11-12T09:02:08.983-08:00Buck Institute, partner spawn startup<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;"><tbody>
<tr><td style="text-align: center;"><a href="http://4.bp.blogspot.com/-RVN927FIX3M/UKErXi2YhmI/AAAAAAAABaQ/RVfcg_5j_wI/s1600/buck-institute-partner-spawn-startup.jpeg" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" height="200" src="http://4.bp.blogspot.com/-RVN927FIX3M/UKErXi2YhmI/AAAAAAAABaQ/RVfcg_5j_wI/s200/buck-institute-partner-spawn-startup.jpeg" width="145" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Stelios Tzannis and Brian Kennedy.</td></tr>
</tbody></table>
<a href="http://www.bizjournals.com/sanfrancisco/print-edition/2012/11/09/buck-institute-partner-spawn-startup.html" style="background-color: white; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;">The Buck Institute for Research on Aging and a for-profit partner are spinning out their research into a new company.</a><br />
<div style="background-attachment: initial; background-clip: initial; background-color: white; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 20px; padding-left: 0px; padding-right: 20px; padding-top: 0px; vertical-align: baseline;">
Delos Pharmaceuticals Inc., which is seeking about $6 million in a Series A fundraising round, is focusing on developing drugs that could target neurodegnerative diseases, cancer, cardiovascular disease and metabolic diseases such as lupus. The company, with CEO <a href="http://www.bizjournals.com/sanfrancisco/search/results?q=Stelios%20Tzannis" style="color: #1d5db1; padding-right: 0px; text-decoration: none;">Stelios Tzannis</a> as its sole employee, is housed at the Novato-based Buck Institute.<br />
It is the first company spun off by the 13-year-old institute, said Buck President and CEO <a href="http://www.bizjournals.com/sanfrancisco/search/results?q=Brian%20Kennedy" style="color: #1d5db1; padding-right: 0px; text-decoration: none;">Brian Kennedy</a>, but there will be more.</div>
Anonymoushttp://www.blogger.com/profile/02615979727918182784noreply@blogger.com0tag:blogger.com,1999:blog-6845058406768528919.post-72862390331407252522012-11-07T15:15:00.000-08:002012-11-07T15:15:36.354-08:00Cerus to pursue U.S. approval of plasma safety system<a href="http://www.bizjournals.com/sanfrancisco/blog/biotech/2012/11/cerus-blood-safety-cers-intercept.html" style="background-color: white; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;">The Food and Drug Administration will allow Cerus Corp. to submit a premarket application toward approval of its blood safety system, the company said Wednesday.</a><br />
<div style="background-attachment: initial; background-clip: initial; background-color: white; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 20px; padding-left: 0px; padding-right: 20px; padding-top: 0px; vertical-align: baseline;">
More than 80 blood centers in 17 European and Middle Eastern countries use the Concord-based company's (NASDAQ: CERS) Intercept system to neutralize pathogens in platelets and/or plasma, the clear yellowish liquids essential for clotting. But because two studies failed and a collaboration with Baxter fell apart, Cerus <a href="http://www.bizjournals.com/sanfrancisco/blog/biotech/2011/09/cerus-blood-novartis-baxter-pathogens.html" style="color: #1d5db1; padding-right: 0px; text-decoration: none;">hasn't been able to win U.S. approval</a> for its system for screening platelets, plasma or red blood cells.</div>
Anonymoushttp://www.blogger.com/profile/02615979727918182784noreply@blogger.com0tag:blogger.com,1999:blog-6845058406768528919.post-34398611434760070912012-11-06T14:58:00.000-08:002012-11-06T15:41:45.320-08:00Latest Genentech breast cancer drug, T-DM1, faces FDA decision by Feb. 26<a href="http://www.bizjournals.com/sanfrancisco/blog/biotech/2012/11/genentech-roche-t-dm1-breast-cancer.html" style="background-color: white; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;">Genentech Inc.'s experimental cancer drug T-DM1 is heading for a Feb. 26 decision date with the Food and Drug Administration.</a><br />
<div style="background-attachment: initial; background-clip: initial; background-color: white; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 20px; padding-left: 0px; padding-right: 20px; padding-top: 0px; vertical-align: baseline;">
The South San Francisco-based U.S. subsidiary of Switzerland's Roche Group said Tuesday that the FDA accepted the company's application for T-DM1, or trastuzumab emtansine, for use by women with HER2-positive metastatic breast cancer. By giving the drug "priority review," the FDA will cut four months off its review time, bringing its decision date on approval to Feb. 26.</div>
Anonymoushttp://www.blogger.com/profile/02615979727918182784noreply@blogger.com0tag:blogger.com,1999:blog-6845058406768528919.post-14022314520657167102012-11-05T17:40:00.002-08:002012-11-05T17:41:40.361-08:00Pharmacyclics stock sags on disappointing clinical results<span class="Apple-style-span" style="background-color: white; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;"><a href="http://www.bizjournals.com/sanjose/blog/2012/11/pharmacyclics-closes-down-more-than-10.html">Cancer drug maker Pharmacyclics Inc.’s stock dropped almost 20 percent at one point Monday, after it released disappointing trial data.</a></span><br />
<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; text-align: right;"><tbody>
<tr><td style="text-align: center;"><a href="http://2.bp.blogspot.com/-H6PvZ7rFxQQ/UJhqXseSAdI/AAAAAAAABZw/Uy5ShCDqnH4/s1600/baybio-pharmacyclics.jpg" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" height="133" src="http://2.bp.blogspot.com/-H6PvZ7rFxQQ/UJhqXseSAdI/AAAAAAAABZw/Uy5ShCDqnH4/s200/baybio-pharmacyclics.jpg" width="200" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Pharmacyclics CEO Robert Duggan and CEO Maky Zanganeh.</td></tr>
</tbody></table>
<span class="Apple-style-span" style="background-color: white; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;">Pharmacyclics announced that a group of multiple myeloma patients it was testing its drug on did not experience tumor shrinkage. According to the Associated Press, the company will now try testing it in higher doses and in combination with other drugs.</span>Anonymoushttp://www.blogger.com/profile/02615979727918182784noreply@blogger.com0tag:blogger.com,1999:blog-6845058406768528919.post-5169820649298572942012-11-05T16:16:00.001-08:002012-11-05T16:17:42.337-08:00Nile Therapeutics CEO takes 99.6% cut in pay -- but maybe not for long<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;"><tbody>
<tr><td style="text-align: center;"><a href="http://2.bp.blogspot.com/-kLxe-jmzEAU/UJhWvHAY7_I/AAAAAAAABZQ/qFVByNaja7I/s1600/darlene-horton-nile-therapeutics-pay-cut.jpeg" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" height="195" src="http://2.bp.blogspot.com/-kLxe-jmzEAU/UJhWvHAY7_I/AAAAAAAABZQ/qFVByNaja7I/s200/darlene-horton-nile-therapeutics-pay-cut.jpeg" width="200" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Nile CEO Dr. Darlene Horton.</td></tr>
</tbody></table>
<a href="http://www.bizjournals.com/sanfrancisco/blog/biotech/2012/11/darlene-horton-nile-therapeutics-pay-cut.html" style="background-color: white; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;">Dr. Darlene Horton is taking one in the pocket book for the Nile Therapeutics Inc. team -- at least for the next few weeks.</a><br />
<div style="background-attachment: initial; background-clip: initial; background-color: white; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 20px; padding-left: 0px; padding-right: 20px; padding-top: 0px; vertical-align: baseline;">
Horton, who in August was given a monthly salary of $28,314 as she was named CEO of the tiny San Mateo heart drug developer, will take a pay cut to $100 a month until Nile completes an interim financing deal.<br />
But there's a greater incentive than just pay for performance here -- more like pay for survival. Nile (OTC: NLTX) said in a Securities and Exchange Commission filing Monday that it has enough cash to last through only the end of this month.<br />
In other words, the clock is ticking for Horton and Nile.</div>
Anonymoushttp://www.blogger.com/profile/02615979727918182784noreply@blogger.com0tag:blogger.com,1999:blog-6845058406768528919.post-81707476553853072412012-11-05T12:06:00.004-08:002012-11-05T12:07:08.974-08:00Pathworks Diagnostics names Lee McCracken as CEO<a href="http://www.bizjournals.com/sanjose/news/2012/11/05/pathworks-diagnostics-names-lee.html" style="background-color: white; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;">Lee McCracken has been named chief executive officer of Pathworks Diagnostics Inc.</a><br />
<div style="background-attachment: initial; background-clip: initial; background-color: white; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 20px; padding-left: 0px; padding-right: 20px; padding-top: 0px; vertical-align: baseline;">
The Redwood City-based cancer diagnostics company <a href="http://www.businesswire.com/news/home/20121105005780/en/Pathwork-Diagnostics-Appoints-Lee-McCracken-CEO" style="color: #1d5db1; padding-right: 0px; text-decoration: none;" target="_blank">said in a release</a> that McCracken was most recently corporate head of business development at Prometheus Laboratories.</div>
Anonymoushttp://www.blogger.com/profile/02615979727918182784noreply@blogger.com0tag:blogger.com,1999:blog-6845058406768528919.post-45935655891779973632012-11-05T10:20:00.001-08:002012-11-05T10:20:48.212-08:00BioMarin shares rise on data from late-stage rare disease trial<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;"><tbody>
<tr><td style="text-align: center;"><a href="http://1.bp.blogspot.com/-vTHBl7kxAiQ/UJgDPl1psEI/AAAAAAAABYs/W6TRusc58NE/s1600/biomarin-galns-mps-iva-orphan-disease.jpeg" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" height="200" src="http://1.bp.blogspot.com/-vTHBl7kxAiQ/UJgDPl1psEI/AAAAAAAABYs/W6TRusc58NE/s200/biomarin-galns-mps-iva-orphan-disease.jpeg" width="133" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">BioMarin CEO Jean-Jacques Bienaime.</td></tr>
</tbody></table>
<a href="http://www.bizjournals.com/sanfrancisco/blog/biotech/2012/11/biomarin-galns-mps-iva-orphan-disease.html" style="background-color: white; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;">BioMarin Pharmaceutical Inc. will seek regulatory approval early next year of a drug to treat a crippling, inherited disease, after a late-stage clinical trial showed that its hit its goal of helping patients walk farther, the company said Monday.</a><br />
<div style="background-attachment: initial; background-clip: initial; background-color: white; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 20px; padding-left: 0px; padding-right: 20px; padding-top: 0px; vertical-align: baseline;">
On the news, shares of the Novato-based drug developer (NASDAQ: BMRN) jumped 29 percent, or $10.84 per share, through mid-afternoon trading to $48.25.<br />
Although the disease -- called Mucopolysaccharidosis Type IVA, or MPS IVA -- affects just 3,000 patients, so-called orphan disease drug developers can charge six figures for the treatments. What's more, insurers generally will cover the cost of drugs that significantly improve or save patients' lives.</div>
Anonymoushttp://www.blogger.com/profile/02615979727918182784noreply@blogger.com0tag:blogger.com,1999:blog-6845058406768528919.post-67812701546044423292012-11-02T12:24:00.000-07:002012-11-02T12:24:20.442-07:00UCSF partners schizophrenia treatments<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;"><tbody>
<tr><td style="text-align: center;"><a href="http://4.bp.blogspot.com/-Wg4KMW9uglw/UJQdfkH1HYI/AAAAAAAABYM/KhPr2GAQPVk/s1600/ucsf-partners-schizophrenia-treatments.jpeg" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" height="200" src="http://4.bp.blogspot.com/-Wg4KMW9uglw/UJQdfkH1HYI/AAAAAAAABYM/KhPr2GAQPVk/s200/ucsf-partners-schizophrenia-treatments.jpeg" width="120" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Bob Bennett and Rachel Loewy.</td></tr>
</tbody></table>
<a href="http://www.bizjournals.com/sanfrancisco/print-edition/2012/11/02/ucsf-partners-schizophrenia-treatments.html" style="background-color: white; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;">Innovative treatment for schizophrenia by the Family Service Agency and researchers at UC San Francisco shows great promise in improving patients’ mental health and cutting costs.</a><br />
<div style="background-attachment: initial; background-clip: initial; background-color: white; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 20px; padding-left: 0px; padding-right: 20px; padding-top: 0px; vertical-align: baseline;">
The disease, which usually strikes in adolescence and can last a lifetime, affects an estimated 6,000 San Franciscans and 70,000 in the Bay Area.<br />
About 170 local patients have gone through the Prevention and Recovery in Early Psychosis or PREP program, which emphasizes early intervention, counseling, cognitive training and use of fewer pharmaceuticals in lower doses to treat the mental illness. Specialized software from San Francisco-based Posit Science trains schizophrenic patients to distinguish hallucinations from rational thinking — which may help alter how their brains process information.</div>
Anonymoushttp://www.blogger.com/profile/02615979727918182784noreply@blogger.com0tag:blogger.com,1999:blog-6845058406768528919.post-18716312663200707362012-11-02T12:19:00.001-07:002012-11-02T12:19:35.121-07:00BNBuilders see project growth in health care, colleges<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;"><tbody>
<tr><td style="text-align: center;"><a href="http://4.bp.blogspot.com/-u_lOhs04PO4/UJQcjedL8cI/AAAAAAAABYE/3NO3u7dQqkg/s1600/bnbuilders-see-project-growth-in.jpeg" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" height="120" src="http://4.bp.blogspot.com/-u_lOhs04PO4/UJQcjedL8cI/AAAAAAAABYE/3NO3u7dQqkg/s200/bnbuilders-see-project-growth-in.jpeg" width="200" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">BNBuilders' David Becker (left) and Sean Truesdale.</td></tr>
</tbody></table>
<a href="http://www.bizjournals.com/sanjose/print-edition/2012/11/02/bnbuilders-see-project-growth-in.html" style="background-color: white; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;">David Becker and Sean Truesdale, principals at BNBuilders Inc.'s Redwood City office, are expecting a wave of projects to wash over the South Bay’s construction industry in the next year.</a><br />
<div style="background-attachment: initial; background-clip: initial; background-color: white; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 20px; padding-left: 0px; padding-right: 20px; padding-top: 0px; vertical-align: baseline;">
But 2011 ended on a strong note for BNBuilders, which posted $100 million in revenue from Silicon Valley projects. Those projects ranged from health care to data centers to universities.</div>
Anonymoushttp://www.blogger.com/profile/02615979727918182784noreply@blogger.com2tag:blogger.com,1999:blog-6845058406768528919.post-68089773015324670272012-11-02T12:05:00.000-07:002012-11-02T12:05:25.022-07:00Patients' tales, biotech legends add weight to BayBio awards<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;"><tbody>
<tr><td style="text-align: center;"><a href="http://3.bp.blogspot.com/-H24lY4Tt-Sc/UJQY7QKGKZI/AAAAAAAABXk/ndXYCmULB5I/s1600/BayBio-HerbBoyer.jpg" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" height="200" src="http://3.bp.blogspot.com/-H24lY4Tt-Sc/UJQY7QKGKZI/AAAAAAAABXk/ndXYCmULB5I/s200/BayBio-HerbBoyer.jpg" width="150" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Genentech co-founder Herb Boyer.</td></tr>
</tbody></table>
<span class="Apple-style-span" style="background-color: white; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;"><a href="http://www.bizjournals.com/sanfrancisco/blog/biotech/2012/11/baybio-pantheon-onyx-kyprolis-patients.html">When two or more biotechs are gathered, you hear the usual phrases, including the old standby, “We're serving patients with unmet medical needs.”</a></span><br />
<span class="Apple-style-span" style="background-color: white; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;">Box checked, move on to other things and the phrase quietly floats away.</span><br />
<div style="background-attachment: initial; background-clip: initial; background-color: white; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 20px; padding-left: 0px; padding-right: 20px; padding-top: 0px; vertical-align: baseline;">
BayBio, Northern California’s life sciences industry trade group, has been beating the “for the patients” drum for the past couple of years especially -- and it didn’t stop at the organization’s annual Pantheon event Thursday night. Problem is, when you hear rote phrases so often, they start to bounce off of you.<br />
That is, until something like this year’s Pantheon ceremony. Many of the companies winning BayBio's DiNA awards brought patients with them to accept their plaques; some actually let patients tell their stories.<br />
Putting patients in front of corporate slide decks is needed by the biotech industry, which has been wringing its collective hands over cuts in research funding and the drought of venture capital cash. Telling those stories, or actually helping patients tell their own stories outside of industry settings, could win over leery legislators and a weary public that feels bombarded with stories of unsafe drugs and failed clinical trials.</div>
Anonymoushttp://www.blogger.com/profile/02615979727918182784noreply@blogger.com32tag:blogger.com,1999:blog-6845058406768528919.post-10305503673182753782012-11-01T18:09:00.001-07:002012-11-01T18:09:13.154-07:00Art and Drue Gensler make $5 million gift to the Buck Institute<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;"><tbody>
<tr><td style="text-align: center;"><a href="http://4.bp.blogspot.com/-Koc8GlkqZz4/UJMdKCHp79I/AAAAAAAABXE/4uavVs3T6jI/s1600/art-gensler-buck-institute-gift.jpeg" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" height="200" src="http://4.bp.blogspot.com/-Koc8GlkqZz4/UJMdKCHp79I/AAAAAAAABXE/4uavVs3T6jI/s200/art-gensler-buck-institute-gift.jpeg" width="195" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Art Gensler.</td></tr>
</tbody></table>
<span class="Apple-style-span" style="background-color: white; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;"><a href="http://www.bizjournals.com/sanfrancisco/blog/biotech/2012/11/art-gensler-buck-institute-gift.html">San Francisco architect Art Gensler </a></span><span class="Apple-style-span" style="background-color: white; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;"><a href="http://www.bizjournals.com/sanfrancisco/blog/biotech/2012/11/art-gensler-buck-institute-gift.html">and his wife Drue have donated $5 million to the Buck Institute for Research on Aging, the largest single individual gift from an individual to the Novato research center</a>.</span>Anonymoushttp://www.blogger.com/profile/02615979727918182784noreply@blogger.com0tag:blogger.com,1999:blog-6845058406768528919.post-8992286628336864792012-11-01T17:43:00.001-07:002012-11-01T17:45:32.542-07:00Pfizer, Bristol-Myers Squibb to fund study of Portola's blood-thinner antidote<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;"><tbody>
<tr><td style="text-align: center;"><a href="http://2.bp.blogspot.com/-ns8o4wZwuEM/UJMXD97LqCI/AAAAAAAABWk/8TGLj_ixZu4/s1600/pfe-bmy-portola-factor-xa-antidote.jpeg" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" height="157" src="http://2.bp.blogspot.com/-ns8o4wZwuEM/UJMXD97LqCI/AAAAAAAABWk/8TGLj_ixZu4/s200/pfe-bmy-portola-factor-xa-antidote.jpeg" width="200" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Portola CEO Bill Lis.</td></tr>
</tbody></table>
<a href="http://www.bizjournals.com/sanfrancisco/blog/biotech/2012/11/pfe-bmy-portola-factor-xa-antidote.html" style="background-color: white; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;">Portola Pharmaceuticals Inc. will get an undisclosed amount of cash in a deal with Bristol-Myers Squibb Co. and Pfizer Inc. to test its experimental treatment to reverse the effect of blood-thinning Factor Xa inhibitor drugs, the company said Thursday</a><span class="Apple-style-span" style="background-color: white; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;">.</span><br />
<div style="background-attachment: initial; background-clip: initial; background-color: white; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 20px; padding-left: 0px; padding-right: 20px; padding-top: 0px; vertical-align: baseline;">
The antidote, called PRT-4445, is supposed to reverse the anticoagulation work of so-called Factor Xa inhibitors, including Eliquis from Bristol-Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE) and South San Francisco-based Portola's betrixaban.</div>
Anonymoushttp://www.blogger.com/profile/02615979727918182784noreply@blogger.com0tag:blogger.com,1999:blog-6845058406768528919.post-34684300260586268512012-11-01T11:44:00.000-07:002012-11-01T11:44:49.562-07:00Advanced Cell Diagnostics lines up $12M Series B round<span class="Apple-style-span" style="background-color: white; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;"><a href="http://www.bizjournals.com/sanfrancisco/blog/biotech/2012/11/advanced-cell-diagnostics-funding-vc.html">Diagnostic test developer Advanced Cell Diagnostics Inc. completed a $12 million Series B financing, led by New Leaf Venture Partners</a>.</span><br />
<div style="background-attachment: initial; background-clip: initial; background-color: white; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 20px; padding-left: 0px; padding-right: 20px; padding-top: 0px; vertical-align: baseline;">
The Hayward company, which developed its RNAscope technology to detect and quantify RNA biomarkers, said existing investor Morningside Ventures also participated in the round.</div>
Anonymoushttp://www.blogger.com/profile/02615979727918182784noreply@blogger.com0tag:blogger.com,1999:blog-6845058406768528919.post-60643077087953523862012-10-31T11:14:00.002-07:002012-10-31T11:15:10.374-07:00BioMarin licenses North American rights to rare disease drug, invests $5M in Catalyst Pharmaceutical Partners<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;"><tbody>
<tr><td style="text-align: center;"><a href="http://2.bp.blogspot.com/-vmYLH_c7s48/UJFqe12wq1I/AAAAAAAABWE/bIQz0_i_Geg/s1600/biomarin-catalyst-firdapse-lems.jpeg" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" height="200" src="http://2.bp.blogspot.com/-vmYLH_c7s48/UJFqe12wq1I/AAAAAAAABWE/bIQz0_i_Geg/s200/biomarin-catalyst-firdapse-lems.jpeg" width="143" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Jean-Jacques Bienaime.</td></tr>
</tbody></table>
<a href="http://www.bizjournals.com/sanfrancisco/blog/biotech/2012/10/biomarin-catalyst-firdapse-lems.html" style="background-color: white; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;">BioMarin Pharmaceutical Inc. has licensed North American rights to its rare disease drug Firdapse and is making a $5 million investment in a Florida company that will carry on with a Phase III trial of the drug in the United States.</a><br />
<div style="background-attachment: initial; background-clip: initial; background-color: white; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 20px; padding-left: 0px; padding-right: 20px; padding-top: 0px; vertical-align: baseline;">
The investment from Novato-based BioMarin (NASDAQ: BMRN) will help Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) complete an ongoing Phase III clinical trial of Firdapse, which treats patients with the potentially fatal autoimmune disorder Lambert-Eaton Myasthenic Syndrome, or LEMS.<br />
BioMarin will retain its rights to Firdapse elsewhere in the world.</div>
Anonymoushttp://www.blogger.com/profile/02615979727918182784noreply@blogger.com0tag:blogger.com,1999:blog-6845058406768528919.post-68994918798157507472012-10-30T06:18:00.000-07:002012-10-30T06:18:52.623-07:00Neuraltus moving Lou Gehrig's disease drug into Phase III<a href="http://www.bizjournals.com/sanfrancisco/blog/biotech/2012/10/als-lou-gehrigs-disease-neuraltus-np001.html" style="background-color: white; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;">Neuraltus Pharmaceuticals Inc. will take its experimental Lou Gehrig’s disease drug into Phase III next year.</a><br />
<div style="background-color: white; border: 0px; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px; outline: 0px; padding: 0px 20px 20px 0px; vertical-align: baseline;">
Although the drug didn’t hit its pre-defined goals in a mid-stage clinical trial, the company said Tuesday, an analysis of the results indicated that the drug stopped the disease, also known as amyotrophic lateral sclerosis, from progressing.<br />
The news is significant for patients with the rare and fatal muscle-crippling disease because there is only one drug approved for ALS and it extends patients’ lives only by weeks.<br />
It also is a victory for the small, privately held Palo Alto company, which is developing the drug in a disease that is poorly understood and where much-larger Biogen Idec (NASDAQ: BIIB) <a href="http://www.bizjournals.combostonnews/2011/03/31/biogen-launches-als-drug-trial.html" style="color: #1d5db1; padding-right: 0px; text-decoration: none;">also has an ALS program in Phase III</a>. It also could set up the company to be sold to a larger biotech or pharmaceutical company or strike a collaboration deal.<br />
Yet, perhaps most of all, the decision to move forward with the drug, called NP-001, demonstrates the power of patients to fight for a drug they believe will alter the course of a disease that can kill patients within three to five years of diagnosis. <a href="http://www.bizjournals.comsanfranciscoprint-edition/2011/09/02/patients-enlist-in-fight-against-als.html" style="color: #1d5db1; padding-right: 0px; text-decoration: none;">A core group of ALS patients and their caregivers fought to fill Neuraltus’ Phase II trial.</a></div>
Anonymoushttp://www.blogger.com/profile/02615979727918182784noreply@blogger.com1tag:blogger.com,1999:blog-6845058406768528919.post-20983424055849461152012-10-29T13:01:00.001-07:002012-10-29T13:01:38.381-07:00How Massachusetts' Bluebird Bio tapped California's stem cell agency for cash, clinical trial help<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;"><tbody>
<tr><td style="text-align: center;"><a href="http://3.bp.blogspot.com/-9U1g-bhGu44/UI7gQvzN8EI/AAAAAAAABVk/7gK30PWDNEo/s1600/DavidsonDavid.jpeg" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" height="132" src="http://3.bp.blogspot.com/-9U1g-bhGu44/UI7gQvzN8EI/AAAAAAAABVk/7gK30PWDNEo/s200/DavidsonDavid.jpeg" width="200" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Bluebird Bio's David Davidson.</td></tr>
</tbody></table>
<a href="http://www.bizjournals.com/sanfrancisco/blog/biotech/2012/10/cirm-stem-cells-bluebird-bio-blood.html" style="background-color: white; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;">California’s stem cell research funding agency took another step toward putting more potential therapies into human clinical trials.</a><br />
<div style="background-attachment: initial; background-clip: initial; background-color: white; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 20px; padding-left: 0px; padding-right: 20px; padding-top: 0px; vertical-align: baseline;">
The <a class="ct saveLink" ct="APT: Company Link" href="http://www.bizjournals.com/profiles/company/us/ca/san_francisco/california_institute_for_regenerative_medicine/3269106/" style="color: #1d5db1; padding-right: 0px; text-decoration: none;">California Institute for Regenerative Medicine</a> awarded $9.3 million Thursday to Cambridge, Mass.-based Bluebird Bio and $10.1 million to ViaCyte Inc. of San Diego.<br />
Bluebird is using stem cells and gene therapy to target young patients with the blood disorder beta-thalassemia. ViaCyte is working on an embryonic stem cell-based therapy for patients with insulin-dependent diabetes.<br />
The awards are important because San Francisco-based CIRM, which is funded by California state bonds after voters in 2004 approved Proposition 71, to date has spent hundreds of millions of dollars on basic science and supporting the construction of new stem cell science buildings at places like the <a class="ct saveLink" ct="APT: Company Link" href="http://www.bizjournals.com/profiles/company/us/ca/san_francisco/university_of_california_san_francisco/3240762/" style="color: #1d5db1; padding-right: 0px; text-decoration: none;">University of California, San Francisco</a>, <a class="ct saveLink" ct="APT: Company Link" href="http://www.bizjournals.com/profiles/company/us/ca/stanford/stanford_university/3287720/" style="color: #1d5db1; padding-right: 0px; text-decoration: none;">Stanford University</a> and the<a class="ct saveLink" ct="APT: Company Link" href="http://www.bizjournals.com/profiles/company/us/ca/novato/buck_institute_for_age_research/3291092/" style="color: #1d5db1; padding-right: 0px; text-decoration: none;">Buck Institute for Age Research</a> in Novato.<br />
I spoke recently with <a href="http://www.bizjournals.com/sanfrancisco/search/results?q=David%20Davidson" style="color: #1d5db1; padding-right: 0px; text-decoration: none;">David Davidson</a>, chief medical officer of Bluebird Bio, about the company’s experimental stem cell treatment, called LentiGlobin, how a Massachusetts company came to win money from a California taxpayer-funded initiative (the answer might surprise you) and Bluebird’s upcoming clinical trial.</div>
Anonymoushttp://www.blogger.com/profile/02615979727918182784noreply@blogger.com0tag:blogger.com,1999:blog-6845058406768528919.post-90379485176169537622012-10-28T14:39:00.001-07:002012-10-28T14:39:46.576-07:00Gladstone, Stanford research offers new game plan for drugs targeting ALS<a href="http://www.bizjournals.com/sanfrancisco/blog/biotech/2012/10/gladstone-stanford-als-lou-gehrigs.html" style="background-color: white; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;">Faking out a key player linked to amyotrophic lateral sclerosis could provide a new game plan in drug researchers’ battle against the deadly disorder also known as Lou Gehrig’s disease, according to scientists at the Gladstone Institutes and Stanford University</a><span style="background-color: white; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;">.</span><br />
<div style="background-color: white; border: 0px; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px; outline: 0px; padding: 0px 20px 20px 0px; vertical-align: baseline;">
The work is no small feat. The protein implicated in ALS, which slowly destroys the nerve cells that control muscle movement even while patients’ minds remain intact, also is critical for the survival of cells, so researchers essentially found a way of luring excess toxic amounts of the protein, called TDP-43.<br />
The findings from the Gladstone and Stanford researchers, published Sunday in the online version of the science journal<em style="background-color: transparent; border: 0px; font-family: arial; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;">Nature Genetics</em>, mean little for the survival of ALS patients today. Researchers worked with yeast cells and neurons from rats -- one of the earliest stages in scientific discovery -- and even if a drug were found tomorrow it would likely take a decade or more to run through safety and efficacy trials in humans.<br />
Still, the discovery could provide drug researchers with a new path for blocking the toxic accumulation of TDP-43 at a time when there is only one Food and Drug Administration-approved drug to treat ALS.</div>
Anonymoushttp://www.blogger.com/profile/02615979727918182784noreply@blogger.com0tag:blogger.com,1999:blog-6845058406768528919.post-69326583439478920302012-10-24T22:30:00.001-07:002012-10-24T22:31:03.599-07:00Ex-Codexis CEO unveils startup around enzymes to convert natural gas<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;"><tbody>
<tr><td style="text-align: center;"><a href="http://1.bp.blogspot.com/-b3oy71iLwgg/UIjOWG7BdpI/AAAAAAAABVA/Xcf9KfN9zEg/s1600/ex-codexis-ceo-unveils-new-startup.jpeg" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" height="132" src="http://1.bp.blogspot.com/-b3oy71iLwgg/UIjOWG7BdpI/AAAAAAAABVA/Xcf9KfN9zEg/s200/ex-codexis-ceo-unveils-new-startup.jpeg" width="200" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Alan Shaw of Calysta Energy.</td></tr>
</tbody></table>
<a href="http://www.bizjournals.com/sanfrancisco/blog/2012/10/ex-codexis-ceo-unveils-new-startup.html" style="background-color: white; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;">Alan Shaw, the effusive former head of enzyme company Codexis, has reemerged as CEO of San Francisco-based startup Calysta Energy.</a><br />
<div style="background-color: white; border: 0px; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px; outline: 0px; padding: 0px 20px 20px 0px; vertical-align: baseline;">
And, spoiler alert, he’s got some new freedom and incentive to talk about why he thinks biofuels companies are failing – and why Calysta is taking a different approach.</div>
Anonymoushttp://www.blogger.com/profile/02615979727918182784noreply@blogger.com0tag:blogger.com,1999:blog-6845058406768528919.post-64317713414788917772012-10-24T13:31:00.002-07:002012-10-24T13:32:20.544-07:00BioMarin cuts ribbon on new San Rafael campus<div class="separator" style="clear: both; text-align: center;">
<a href="http://2.bp.blogspot.com/-woL2v4Qw34A/UIhQE6Is7oI/AAAAAAAABUc/26GDy9ypgK8/s1600/biomarin-cuts-ribbon-on-new-san-rafael.jpeg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><br /><img border="0" height="149" src="http://2.bp.blogspot.com/-woL2v4Qw34A/UIhQE6Is7oI/AAAAAAAABUc/26GDy9ypgK8/s200/biomarin-cuts-ribbon-on-new-san-rafael.jpeg" width="200" /></a></div>
<div style="background-attachment: initial; background-clip: initial; background-color: white; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 20px; padding-left: 0px; padding-right: 20px; padding-top: 0px; vertical-align: baseline;">
<a href="http://www.bizjournals.com/sanfrancisco/blog/biotech/2012/10/biomarin-cuts-ribbon-on-new-san-rafael.html">BioMarin Pharmaceutical Inc. celebrated the opening of a new campus in San Rafael on Thursday.</a><br />
The event was attended by California Lt. Gov. <a href="http://www.bizjournals.com/sanfrancisco/search/results?q=Gavin%20Newsom" style="color: #1d5db1; padding-right: 0px; text-decoration: none;">Gavin Newsom</a> and other VIPs, as well as <a href="http://www.bizjournals.com/sanfrancisco/search/results?q=Jean-Jacques%20Bienaim%C3%A9" style="color: #1d5db1; padding-right: 0px; text-decoration: none;">Jean-Jacques Bienaimé</a>, BioMarin's (NASDAQ: BMRN) CEO.</div>
Anonymoushttp://www.blogger.com/profile/02615979727918182784noreply@blogger.com0tag:blogger.com,1999:blog-6845058406768528919.post-74204292973279624322012-10-24T13:29:00.006-07:002012-10-24T13:32:06.333-07:00Auxogyn teams with Merck Serono on in vitro fertilization embryo test<a href="http://www.bizjournals.com/sanfrancisco/blog/biotech/2012/10/auxogyn-merck-serono-ivf-embryo-test.html" style="background-color: white; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px;">Auxogyn Inc. made a deal with Merck Serono for advice and support in developing and marketing a test for embryos during in vitro fertilization.</a><br />
<div style="background-attachment: initial; background-clip: initial; background-color: white; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; color: #444444; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; line-height: 20px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 20px; padding-left: 0px; padding-right: 20px; padding-top: 0px; vertical-align: baseline;">
Menlo Park-based Auxogyn and Darmstadt, Germany's Merck Serono will work together on the Early Embryo Viability Assessment, or Eeva Test. It was approved in July by European regulators -- getting the CE mark which allows it to be sold in the European Union -- and it is pending before the U.S. Food and Drug Administration.</div>
Anonymoushttp://www.blogger.com/profile/02615979727918182784noreply@blogger.com0